FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 4, 2006--Andrx Corporation (Nasdaq:ADRX - News) announced today that Takeda Global Research & Development Center Inc. filed a New Drug Application (NDA) for a combination product consisting of Takeda's ACTOS® (pioglitazone HCl) and Andrx's extended-release metformin to the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
